Express Pharma

Sun Pharma enters Japanese prescription market


Acquires 14 prescription brands

Sun Pharma has acquired 14 established prescription brands from Novartis in Japan. According to the agreements entered into between the parties, a wholly-owned subsidiary of Sun Pharma will acquire the portfolio consisting of 14 established prescription brands from Novartis for a cash consideration of $293 million. These brands have combined annualised revenues of approximately $160 million and address medical conditions across several therapeutic areas.

Under the terms of the agreements, Novartis will continue to distribute these brands, for a certain period, pending transfer of all marketing authorisations to Sun Pharma’s subsidiary. The acquired brands will be marketed by a reliable and established local marketing partner under the Sun Pharma label. The local marketing partner will also be responsible for distribution of the brands.

Comments are closed.